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Narcolepsy is characterized by fragmented nighttime sleep and 
frequent arousals. One treatment approach to improve daytime 
symptoms is to consolidate nighttime sleep through decreasing 
arousals. Sodium oxybate is the fi rst FDA-approved medication 
that follows this approach. Benzodiazepines are known to also 
decrease arousals at night and have been proposed to help with 
sleep fragmentation. In one report, clonazepam was shown to 
improve cataplexy in 10 of 14 patients with narcolepsy although 
no improvement in daytime sleepiness was reported. The pur-
pose of this case review was to share our experience of noc-
turnal temazepam on daytime sleepiness in patients with nar-
colepsy as measured by the Epworth Sleepiness Scale (ESS).
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Narcolepsy is characterized by fragmented nighttime sleep and frequent arousals. One treatment approach to improve 
daytime symptoms is to consolidate nighttime sleep through 
decreasing arousals. Sodium oxybate is the fi rst FDA-approved 
medication that follows this approach. Benzodiazepines are 
known to also decrease arousals at night and have been proposed 
to help with sleep fragmentation.1 In one report, clonazepam was 
shown to improve cataplexy in 10 of 14 patients with narcolepsy 
although no improvement in daytime sleepiness was reported.2
The purpose of this case review was to share our experience 
of nocturnal temazepam on daytime sleepiness in patients with 
narcolepsy as measured by the Epworth Sleepiness Scale (ESS).
REpoRt oF CaSES
In this retrospective case series, the records of patients di-
agnosed with narcolepsy and treated with temazepam were 
examined. Diagnosis was based on a combination of poly-
somnography, multiple sleep latency testing, and clinical 
presentation in accordance with the diagnostic criteria from 
the International Classifi cation of Sleep Disorders, 2nd edi-
tion.3 All 7 patients had a history of cataplexy, but only 5 had 
ongoing attacks more often than once a month. Doses of te-
mazepam ranged from 15 mg to 30 mg and were administered 
once nightly prior to bedtime for a minimum of one week. All 
other medications and doses were unchanged during the te-
mazepam titration. Each patient had a quantifi ed measure of 
daytime sleepiness through the ESS both prior to initiation of 
temazepam and at each tolerated dose. Baseline ESS and ESS 
at the highest tolerated temazepam dose were compared using 
a paired sample t-test. Seven patients were included in this re-
view. The age of patients ranged from 9 to 71 years, with a 
mean age of 35 years. They were diagnosed with narcolepsy 
for a mean of 14 years (range 1 to 49 years). Six patients re-
ported a decrease in daytime sleepiness on temazepam, with 
a mean change in ESS score of -5.1 points (range -10 to 1, see 
Figure 1). The mean ESS score was 16.4 prior to initiation of 
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temazepam and was 11.3 on the highest tolerated dose. This 
difference was statistically signifi cant (p = 0.007). Although not 
quantifi ed, four patients who had frequent cataplexy at the time 
of initiation of temazepam reported a subjective improvement 
in frequency of cataplexy, three of whom had improvement in 
their subjective sleepiness. Six of the 7 patients elected to re-
main on the temazepam. See Table 1 for further information on 
sleep characteristics of individual patients.
diSCuSSioN
Nocturnal temazepam may be an option to improve excessive 
daytime sleepiness in patients with narcolepsy. Based on our 
experience, temazepam appears to improve subjective sleepi-
ness as measured by ESS scores and anecdotally improves the 
frequency of cataplexy. Narcolepsy patients are known to have 
fragmented sleep and frequent sleep stage shifts. Therapeutic 
guidelines recommend sodium oxybate as a treatment option 
for cataplexy. Large clinical trials suggest benefi t to excessive 
daytime sleepiness and cataplexy may in part be mediated by 
the drug’s ability to consolidate sleep.4,5 Temazepam may have 
a similar action in patients with narcolepsy by consolidating 
sleep. Unlike sodium oxybate, temazepam is not known to 
increase slow wave sleep.6,7 Our study is limited by the retro-
spective approach and the small sample size. The population is 
mixed, including both pediatric and adult patients, as well as 
patients with and without cataplexy. We also did not perform 
polysomnography immediately prior to and following temaze-
pam use and therefore do not have data to further speculate re-
garding the mechanism. Finally, we used the ESS as a measure 
of daytime sleepiness as opposed to the more objective MSLT. 
One prior study using triazolam showed no change in MSLT, 
which emphasizes the importance of objective measures for 
sleepiness.8 However, triazolam is also a short-acting agent, so 
might not work as well as temazepam.
Of note, the fi ve adult patients in our study had a mean 
decrease in ESS score of 7 points. Our two pediatric patients 
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had a mean decrease of only 1 point. One of these patients had 
an increase in ESS. Given the fact that adults with narcolepsy 
have more arousals from sleep than children, this difference in 
response to temazepam would be expected if the improvement 
in daytime functioning is a result of increased sleep consolida-
tion. Interestingly, one pediatric patient did report improve-
ment in frequency of cataplexy. Although temazepam may be 
an option in the future treatment of narcolepsy patients, fur-
ther prospective, placebo-controlled trials are needed to estab-
lish the effectiveness of temazepam therapy in both children 
and adults.
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Figure 1—Individual changes in ESS with temazepam
table 1—Sleep characteristics for individual patients
patient
Subjective 
















1 Poor 71 F 21 N/A 13.5 14
2 Poor 37 F Yes 20 N/A 15 14
3 Mildly disturbed 38 F 9 5 4 N/A
4 Mildly disturbed 18 M Yes 15 N/A Not recorded 9
5 Mildly disturbed 9 F Yes 13 Not recorded 14 N/A
6 Brief awakenings 14 F 13 N/A 10 N/A
7 Poor 57 F Yes 24 N/A 17 14
